Keywords

• Sitagliptin phosphate
• 654671-78-0
• C16H15F6N5O.H3PO4

Quick Details

• ProName: Sitagliptin phosphate 654671-78-0
• CasNo: 654671-78-0
• Molecular Formula: C16H15F6N5O.H3PO4
• Appearance: detailed in specifcations
• Application: Aripiprazole Intermediate functional...
• DeliveryTime: within 5days
• PackAge: as needed
• Port: China main port
• ProductionCapacity: 500 Metric Ton/Month
• Purity: 99%
• Storage: Keep in dry and cool condition
• Transportation: by air or sea
• LimitNum: 1 Kilogram
• MF: C13H21O3PS

Superiority

Our Services

1.Certificate Of Analysis (COA)

2.Material Safety Data Sheet (MSDS)

3.Route of synthesis (ROS)

4.Method of Aanlysis (MOA)

5.Nuclear Magnetic Resonance (NMR)

6.Packing pictures and loading video before loading

7.Free Sample

9.Factory audit

10.Strong after-sale service

Company information

Henan Sunlake Enterprise Corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East , Africa , South America and some other countries and areas.We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team.We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate.

Details

Sitagliptin phosphate Basic information

New antidiabetic drug DPP-4 inhibitors

Product Name:	Sitagliptin phosphate
Synonyms:	4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate;Sitagliptin phosphate;7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-α]pyrazine-phosphate;(3R)-3-aMino-1-[3-(trifluoroMethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;Sitagliptin phosphate/Sitagliptin phosphate Monohydrate/Sitagliptin;Sitagliptin phosphate 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate
CAS:	654671-78-0
MF:	C16H15F6N5O.H3PO4
MW:	505.31
EINECS:
Product Categories:	All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API;Pharmaceutical intermdiate
Mol File:	654671-78-0.mol

Sitagliptin phosphate Chemical Properties

mp	202-204°C
storage temp.	-20°C Freezer

Safety Information

MSDS Information

 

Sitagliptin phosphate Usage And Synthesis

New antidiabetic drug

Sitagliptin phosphate is dipeptidyl peptidase Ⅳ(DDP-4) inhibitor class of drugs developed by the German Merck company and firstly obtained the US Food and Drug Administration approval for the treatment of type 2 diabetes, is a new antidiabetic drug, can improve the body's own ability to reduce high blood glucose levels, and the relatively increase naturally occurring incretin by inhibiting the activity of this enzyme, including the levels of glucagon-like peptide 1 and glucose-dependent insulinotropic peptide, thereby triggering the pancreas to improve insulin production and stop glucose production in liver, and ultimately reduce the clinical effect of blood glucose concentration. Features of this product is to stimulate insulin secretion, at the same time can alleviate hunger, but does not make weight gain, and also cannot happen hypoglycemia and edema, is not suitable for use in diabetic patients with poor glycemic control and often developed hypoglycemia. By verification of clinical 552 cases of mild to moderate type 2 diabetes, taken once a day Sitagliptin phosphate, once time 100 mg, after taking the drug for 12 weeks, can make glycated hemoglobin reduce 0.6% -1.1%. Incidence of adverse reactions is similar to placebo, the most frequently reported adverse reactions (incidence> 5% and greater than placebo) is a stuffy or runny nose, and sore throat, upper respiratory tract infection and headache. Clinical studies showed that the Sitagliptin phosphate as monotherapy in patients with type 2 diabetes, can make glycated hemoglobin (HbA1c) levels significantly reduce. When in combination with the metformin or TZDs, has a significant role of adjuvant therapy, can focus on three kinds of major defect in type 2 diabetes: insulin resistance, β-cell dysfunction (reduction of insulin release), and α-cell dysfunction